The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer
Open accessAbstract
To grow and metastasize, solid tumours must develop their own blood supply by neo-angiogenesis. Thalidomide inhibits the processing of mRNA encoding peptide molecules including tumour necrosis factor-alpha (TNF-alpha) and the angiogenic factor vascular endothelial growth factor (VEGF). This study investigated the use of continuous low dose Thalidomide in patients with a variety of advanced malignancies. Sixty-six patients (37 women and 29 men; median age, 48 years; range 33-62 years) with advanced measurable cancer (19 ovarian, 18 renal, 17 melanoma, 12 breast cancer) received Thalidomide 100 mg orally every night until disease progression or unacceptable toxicity was encountered. Three of 18 patients with renal cancer showed partial responses and a further three patients experienced stabilization of their disease for up to 6 months. Although no objective responses were seen in the other tumour types, there were significant improvements in patients' sleeping (P < 0.05) and maintained appetite (P < 0.05). Serum and urine concentrations of basic fibroblast growth factor (bFGF), TNF-alpha and VEGF were measured during treatment and higher levels were associated with progressive disease. Thalidomide was well tolerated: Two patients developed WHO Grade 2 peripheral neuropathy and eight patients developed WHO grade 2 lethargy. No patients developed WHO grade 3 or 4 toxicity. Further studies evaluating the use of Thalidomide at higher doses as a single agent for advanced renal cancer and in combination with biochemotherapy regimens are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,627
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Clinical Applications of Research on Angiogenesis
Folkman, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512283332608 · Cited by 2,264
Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., & Folkman, J. (1990) · Nature · doi:10.1038/348555a0 · Cited by 1,299
THALIDOMIDE AND CONGENITAL ABNORMALITIES
Mcbride, W. G. (1961) · The Lancet · doi:10.1016/s0140-6736(61)90927-8 · Cited by 1,141
Intratumor microvessel density as a prognostic factor in cancer.
Weidner, N. (1995) · PubMed Central · Cited by 866
Inhibition of Angiogenesis In Vivo by Interleukin 12
Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J., & Folkman, J. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.8.581 · Cited by 722
Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects
Battegay, E. J. (1995) · Journal of Molecular Medicine · doi:10.1007/bf00192885 · Cited by 537
Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity
Parman, T., Wiley, M. J., & Wells, P. G. (1999) · Nature Medicine · doi:10.1038/8466 · Cited by 495
Jacobson, J. M., Greenspan, J. S., Spritzler, J., Ketter, N., Fahey, J. L., Jackson, J. B., Fox, L., Chernoff, M., Wu, A. W., MacPhail, L. A., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705223362103 · Cited by 420
THALIDOMIDE AND CONGENITAL ABNORMALITIES
Lenz, W., Pfeiffer, R. A., Kosenow, W., & Hayman, D. J. (1962) · The Lancet · doi:10.1016/s0140-6736(62)92665-x · Cited by 379
Dual role of tumor necrosis factor-alpha in angiogenesis.
Fajardo, L. F., Kwan, H. H., Kowalski, J., Prionas, S. D., & ALLISON, A. C. (1992) · PubMed · Cited by 355
THALIDOMIDE AND CONGENITAL ABNORMALITIES
Burley, D. M., & Lenz, W. (1962) · The Lancet · doi:10.1016/s0140-6736(62)91217-5 · Cited by 324
Thalidomide and Congenital Abnormalities
McBride, W. G. (1961) · Springer eBooks · doi:10.1007/978-94-011-6621-8_27 · Cited by 141
Neuropathy After Intake of Thalidomide (Distaval)
Fullerton, P. M., & Kremer, M. (1961) · BMJ · doi:10.1136/bmj.2.5256.855 · Cited by 133
Vascular targeting—a new approach to the therapy of solid tumors
Burrows, F. J., & Thorpe, P. E. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90037-x · Cited by 131
Yoneda, T., Alsina, M. A., Chavez, J. B., Bonewald, L. F., Nishimura, R., & Mundy, G. R. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115106 · Cited by 122
Erhard, H., Rietveld, F. J. R., van Altena, M. C., Br??cker, E.-B., Ruiter, D. J., & de Waal, R. M. W. (1997) · Melanoma Research · doi:10.1097/00008390-199708001-00005 · Cited by 121
Loss of ovarian function promotes angiogenesis in human ovarian carcinoma
Schiffenbauer, Y. S., Abramovitch, R., Meir, G., Nevo, N., Holzinger, M., Itin, A., Keshet, E., & Neeman, M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13203 · Cited by 109
Hamada, J., Cavanaugh, P. G., Lotan, O., & Nicolson, G. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.269 · Cited by 107
Talbot, B., & Brown, P. D. N. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00398-x · Cited by 105
Interleukin-6 and renal cell cancer: Production, regulation, and growth effects
Koo, A. S., Armstrong, C., Bochner, B. H., Shimabukuro, T., Tso, C.-L., deKernion, J. B., & Belldegrun, A. S. (1992) · Cancer Immunology Immunotherapy · doi:10.1007/bf01741856 · Cited by 104
Thalidomide in Crohn's disease
Wettstein, A. R., Meagher, A. P., & Meagher, A. (1997) · The Lancet · doi:10.1016/s0140-6736(05)64206-7 · Cited by 96
Role of soluble mediators in angiogenesis
Bussolino, F., Albini, A., Camussi, G., Presta, M., Viglietto, G., Ziehe, M., & Persico, G. M. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00390-5 · Cited by 94
Thalidomide and Congenital Abnormalities
Lenz, W. (1962) · Springer eBooks · doi:10.1007/978-94-011-6621-8_28 · Cited by 70
Gasparini, G. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00376-0 · Cited by 68
Mizutani, Y., Bonavida, B., Nio, Y., & Yoshida, O. (1994) · The Journal of Urology · doi:10.1016/s0022-5347(17)35347-8 · Cited by 24
Cited by
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
The evolution of thalidomide and its IMiD derivatives as anticancer agents
Bartlett, J. B., Dredge, K., & Dalgleish, A. G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1323 · Cited by 809
Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma
Motzer, R. J., Bacik, J., Schwartz, L. H., Reuter, V., Russo, P., Marion, S., & Mazumdar, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.132 · Cited by 793
Fibroblast Growth Factors: Biology, Function, and Application for Tissue Regeneration
Yun, Y.-R., Won, J. E., Jeon, E., Lee, S., Kang, W., Jo, H., Jang, J.-H., Shin, U. S., & Kim, H.-W. (2010) · Journal of Tissue Engineering · doi:10.4061/2010/218142 · Cited by 712
Franks, M. E., Macpherson, G. R., & Figg, W. D. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16308-3 · Cited by 615
Metadata
- Authors
- Eisen, T., Boshoff, C., Mak, I., Sapunar, F., Vaughan, M. M., Pyle, L., Johnston, S. R. D., Ahern, R., Smith, I. E., & Gore, M. E.
- Venue
- British Journal of Cancer
- Published
- 2000-02
- Volume
- 82
- Issue
- 4
- Pages
- 812-817
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2042774683
- Cited by
- 338
- References
- 29
- FWCI
- 14.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.